IHC 2021 | Approval of anti-CGRP monoclonal antibodies for migraine in Japan

In 2021, galcanezumab, erenumab, and fremanezumab were approved for migraine in Japan, making them the first approved treatments in Japan to inhibit the calcitonin gene-related peptide (CGRP) or block its receptor. Koichi Hirata, MD, Dokkyo Medical University, Sōka, Japan, discusses how this approval has impacted migraine treatment in Japan. Additionally, Dr Hirata talks about a long-term open-label safety study of galcanezumab in Japanese patients with migraine. This interview took place during the International Headache Congress 2021.